Associations of public transport accessibility with walking, obesity, metabolic syndrome and diabetes
Alison Barr, Rebecca Bentley, Julie A Simpson, Jan Scheurer, Neville Owen, David Dunstan, Lukar Thornton, Lauren Krnjacki, Anne Kavanagh
JOURNAL OF TRANSPORT & HEALTH | ELSEVIER SCI LTD | Published : 2016
Objective: To examine associations of public transport system accessibility with walking, obesity, metabolic syndrome and diabetes/impaired glucose regulation. Methods: Associations of public transport accessibility with self-reported walking for transport or recreation and measured biomarkers of chronic disease risk were estimated in 5241 adult residents of 42 randomly selected areas in Australia in 2004/05, drawn from the second wave of a population-based cohort study (AusDiab). Public transport accessibility was objectively measured using an adaptation of the Public Transport Accessibility Levels (PTAL) methodology, comprising both GIS derived spatial and temporal accessibility measures. ..View full abstract
Related Projects (2)
Awarded by National Health and Medical Research Council of Australia
Awarded by National Heart Foundation of Australia
This research was funded by the National Health and Medical Research Council of Australia (Grant no. 324724) and the National Heart Foundation of Australia (Grant no. G07M3175). The AusDiab study was funded by the National Health and Medical Research Council of Australia (Grant no. 233200). The AusDiab study, co-coordinated by the Baker IDI Heart and Diabetes Institute, acknowledges support by the following: Australian Government Department of Health and Ageing, Abbott Australasia, Alphapharm, AstraZeneca, Aventis Pharma, Bristol-Myers Squibb, City Health Centre Diabetes Service Canberra, Diabetes Australia, Healthy Living NT, Eli Lilly Australia, Estate of the late Edward Wilson, GlaxoSmithKline, Jack Brockhoff Foundation, Janssen-Cilag, Kidney Health Australia, Marian & EH Flack Trust, Menzies Research Institute, Merck Sharp & Dohme, New South Wales Health, Northern Territory Department of Health and Families, Novartis, Novo Nordisk, Pfizer, Pratt Foundation, Queensland Health, Roche Diagnostics Australia, Royal Prince Alfred Hospital (Sydney), Sanofi-Synthelabo, South Australia Health, Tasmanian Department of Health and Human Services, Victorian Department of Human Services, and Western Australia Health.